- Conditions
- Chronic Spinal Cord Injury
- Interventions
- NVG-291, Placebo
- Drug
- Lead sponsor
- NervGen Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Pheonix, Arizona • Downey, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 2,415
matching trials from the local directory fallback.
- Conditions
- Primary Evans Syndrome (ES), Primary Immune Thrombocytopenia (ITP)
- Interventions
- ianalumab, thrombopoietin receptor agonist (TPO-RA)
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Torrance, California + 16 more
- Conditions
- HER2-low Hormone Receptor Positive Breast Cancer, Melanoma (Skin Cancer)
- Interventions
- AMXT 1501 Dicaprate, Capivasertib, DFMO, Fulvestrant, Pembrolizumab
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Advanced Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung, Metastatic Non Small Cell Lung Cancer, Non Small Cell Lung Cancer
- Interventions
- Marlotamig, Sarilumab, Ubamatamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more
- Conditions
- Epilepsy, Epilepsy (Treatment Refractory)
- Interventions
- Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Device
- Lead sponsor
- Epiminder America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 16 more
- Conditions
- Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Muscle Weakness, Muscular Diseases, Myasthenia Gravis, Neuromuscular Manifestations
- Interventions
- Cyclophosphamide, Fludarabine, anito-cel
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 10 more
- Conditions
- Preeclampsia
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lymphedema, Breast Cancer
- Interventions
- Conservative Complex Physical Decongestion Therapy, Surgical Intervention
- Procedure
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Rochester, Minnesota + 1 more
- Conditions
- Acute Kidney Injury
- Interventions
- Selective Cytopheretic Device, Standard of Care
- Device · Other
- Lead sponsor
- SeaStar Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
- Conditions
- Multiple Myeloma, Myeloma, Myeloma Multiple
- Interventions
- Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
- Drug
- Lead sponsor
- K36 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- San Francisco, California • Jacksonville, Florida • Miami, Florida + 15 more
- Conditions
- Anemia, Myelodysplastic Syndromes, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis; Anemia, Post-essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis
- Interventions
- DISC-0974
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 31
- States / cities
- Gilbert, Arizona • Duarte, California • Irvine, California + 26 more
- Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
- Interventions
- INCB000928, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 99 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Acinar Cell Carcinoma, Advanced Cancer, Endometrial Cancer, Fallopian Tube Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Peritoneal Cancer
- Interventions
- ART0380, Gemcitabine, Irinotecan
- Drug
- Lead sponsor
- Artios Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Interventions
- Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- National Cancer Institute LAO
- Other
- Eligibility
- 2 Months and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 95 more
- Conditions
- Vulvar Intraepithelial Neoplasia, HPV-Independent, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion, HPV-Associated
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Newly Diagnosed Multiple Myeloma (NDMM)
- Interventions
- AZD0120, Cyclophosphamide, Fludarabine, Lenalidomide, Melphalan (part of ASCT)
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2039
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more
- Conditions
- High Risk Smoldering Multiple Myeloma (HR-SMM)
- Interventions
- Daratumumab, Linvoseltamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- NNC6019-0001, Placebo (NNC6019-0001)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more
- Conditions
- Obesity
- Interventions
- Mayo Clinic Diet, Usual Care
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Brain Tumor, Glioma Glioblastoma Multiforme, Glioma, Malignant, Lung Cancer, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Solid Tumor
- Interventions
- TNG456, abemaciclib
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more
- Conditions
- Untreated Follicular Lymphoma
- Interventions
- BR, R-CHOP, R-CVP, Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 62
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
- Conditions
- Foot Injury
- Interventions
- Modular Carbon Fiber Custom Dynamic Orthosis (CDO), Mono Carbon Fiber Custom Dynamic Orthosis (CDO)
- Device
- Lead sponsor
- Jason Wilken
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- San Diego, California • Iowa City, Iowa • Minneapolis, Minnesota + 2 more
- Conditions
- Oligometastatic Prostate Cancer (OMPC)
- Interventions
- AAA617, gallium (68Ga) gozetotide (25μg), piflufolastat (18F)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 39
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Autoimmune Disorders
- Interventions
- Daratumumab
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 3 more